載入中
NASDAQHealthcareBiotechnology
最新資料
US$1.815
−US$0.205 · -10.15%
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
收盤時
US$1.815
−US$0.205 · -10.15%
盤後
US$1.83
+US$0.015 · +0.83%
10月13日 下午4:23 ET
盤中時間採用ET。市場資料可能有所延遲。
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
日內區間
目前US$1.815
52週區間
目前US$1.815
盤中時間採用ET。市場資料可能有所延遲。
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
日內區間
目前US$1.815
52週區間
目前US$1.815
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | — | — | — | 1230.5萬 USD |
| 毛利 | — | — | — | — | −1230.5萬 USD |
| 研究與開發 | 1.05億 USD | 9379.8萬 USD | 4231.8萬 USD | 3236.1萬 USD | 1230.5萬 USD |
| 銷售、一般及管理費用 | 1894.7萬 USD | 2021.9萬 USD | 1882萬 USD | 1287.6萬 USD | 727.9萬 USD |
| 營業費用 | 1.24億 USD | 1.14億 USD | 6113.8萬 USD | 4523.7萬 USD | 727.9萬 USD |
| 利息收入 | 744.7萬 USD | 1431.7萬 USD | 1079.1萬 USD | 239.2萬 USD | 8.4萬 USD |
| 利息支出 | 422.4萬 USD | 406.8萬 USD | 58.1萬 USD | — | — |
| 折舊和攤銷 | 18.4萬 USD | 17.8萬 USD | 18.4萬 USD | 16.9萬 USD | 4000 USD |
| 營業利益 | −1.24億 USD | −1.14億 USD | −6113.8萬 USD | −4523.7萬 USD | −1958.4萬 USD |
| 淨利 | −1.21億 USD | −1.02億 USD | −5237.1萬 USD | −4285.6萬 USD | −1.01億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$7.00
上漲空間 285.67%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI318.72萬0.00%2.3兆 USD0.03%US$381.32-0.07%
iShares Russell 2000 ETFIWM234.17萬0.00%787.4億 USD0.19%US$276.71-0.43%
Vanguard Extended Market ETFVXF146.35萬0.00%954億 USD0.05%US$232.54-0.42%
iShares Russell 2000 Value ETFIWN86.28萬0.01%137.49億 USD0.24%US$210.99-0.05%
Vanguard Russell 2000 ETFVTWO76.94萬0.00%180億 USD0.06%US$111.77-0.45%
iShares Micro-Cap ETFIWC30.36萬0.02%13.17億 USD0.60%US$179.6-1.13%
Dimensional - US Small Cap ETFDFAS24.69萬0.00%338.04億 USD0.31%US$78.33+0.20%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM17萬0.15%1.16億 USD0.73%US$15.6501-1.25%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
